Microbiome Startup BiomX Raises $24 Million in Series A Round

May 15, 2017

|

CHICAGO (GenomeWeb) – BiomX, a startup focused on microbiome therapeutics via a proprietary microbiome modulation technology platform, said today that it has raised $24 million in Series A venture capital.

OrbiMed, Johnson & Johnson Innovation–JJDC, and Takeda Ventures led the round. Seventure Partners, MiraeAsset, the Japan-Israel Development Fund, and other unspecified European investors also participated, according to Ness Ziona, Israel-based BiomX.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Harder to Breathe

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

Sequence From the Jomon Period

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Shifting Sands of Gene Variant Interpretation

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

This Week in Science

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.

Featured White Papers

Compatibility of liquid biopsy assays on multiple sequencing platforms

BlueBee Data Security & Compliance

Whole Genome Sequencing of Microbial Communities for Scaling Microbiome and Metagenomic Studies

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Jun

17

Featured Webinar

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Menu